Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Deepak L. Bhatt, M.D.

Co-Author

This page shows the publications co-authored by Deepak Bhatt and Dorairaj Prabhakaran.
Connection Strength

0.517
  1. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013 Aug 17; 382(9892):605-13.
    View in: PubMed
    Score: 0.137
  2. Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries. Circulation. 2020 06 16; 141(24):2004-2025.
    View in: PubMed
    Score: 0.055
  3. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart. 2017 08; 103(15):1168-1176.
    View in: PubMed
    Score: 0.044
  4. Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. Am Heart J. 2017 Jun; 188:156-166.
    View in: PubMed
    Score: 0.044
  5. Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Heart Assoc. 2016 11 04; 5(11).
    View in: PubMed
    Score: 0.043
  6. Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. Clin Cardiol. 2016 Sep; 39(9):497-506.
    View in: PubMed
    Score: 0.042
  7. Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. J Am Coll Cardiol. 2016 Mar 22; 67(11):1289-97.
    View in: PubMed
    Score: 0.041
  8. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. J Am Coll Cardiol. 2016 Mar 01; 67(8):936-947.
    View in: PubMed
    Score: 0.041
  9. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Am Heart J. 2015 Oct; 170(4):683-694.e3.
    View in: PubMed
    Score: 0.039
  10. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 Oct 04; 367(14):1297-309.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.